# The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism

> **NCT06381323** · PHASE4 · COMPLETED · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 55 (actual)

## Conditions studied

- Primary Aldosteronism
- Finerenone
- Mineralocorticoid Receptor Antagonist

## Interventions

- **DRUG:** Finerenone

## Key facts

- **NCT ID:** NCT06381323
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06381323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06381323, "The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06381323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*